Kymera Therapeutics (KYMR) Operating Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Operating Leases data on file, last reported at $65.6 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 7.86% year-over-year to $65.6 million in Q1 2026; TTM through Mar 2026 was $65.6 million, a 7.86% decrease from a year earlier, with the FY2025 full-year figure at $67.0 million, down 7.44% from the prior year.
• Operating Leases for Q1 2026 stood at $65.6 million, down from $67.0 million in the prior quarter.
• Over the last five years, Operating Leases for KYMR reached as high as $77.0 million in Q4 2023 and fell as low as $12.1 million in Q4 2022.
• Historically, Operating Leases has averaged $57.5 million across 5 years, with a median of $69.8 million in 2025.
• Across the five-year window, Operating Leases dropped 8.15% in 2022 and jumped 534.18% in 2023, its largest moves.
• Year by year, Operating Leases stood at $12.1 million in 2022, then soared by 534.18% to $77.0 million in 2023, then fell by 5.98% to $72.4 million in 2024, then fell by 7.44% to $67.0 million in 2025, then declined by 2.16% to $65.6 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $65.6 million in Q1 2026, $67.0 million in Q4 2025, and $68.4 million in Q3 2025.